Oxford Biomedica plc (LON:OXB) Receives Consensus Recommendation of "Moderate Buy" from Brokerages

Key Points

• "Moderate Buy" consensus from seven brokerages (six "buy", one "hold") with an average 1‑year target of GBX 687; individual analyst targets include GBX 950 (Stifel), GBX 827 (Jefferies) and GBX 800 (Deutsche Bank).
• Shares opened at GBX 589 with 50‑day/200‑day moving averages of GBX 620.81/664.12 and a 52‑week range of GBX 270–952, and the company has a market cap of £712.1m; however, Oxford Biomedica reported a negative EPS of GBX (26.92) last quarter (forecast -31.08 for the year) and shows negative ROE/net margin alongside a high debt‑to‑equity ratio of 116.74.

Oxford Biomedica plc (LON:OXB - Get Free Report) has been given a consensus rating of "Moderate Buy" by the seven brokerages that are presently covering the company, MarketBeat Ratings reports. One equities research analyst has rated the stock with a hold rating and six have given a buy rating to the company. The average 1 year target price among analysts that have issued a report on the stock in the last year is GBX 687.

A number of equities research analysts have issued reports on OXB shares. Stifel Nicolaus reiterated a "buy" rating and issued a GBX 950 target price on shares of Oxford Biomedica in a research report on Wednesday, March 11th. Deutsche Bank Aktiengesellschaft increased their target price on shares of Oxford Biomedica from GBX 735 to GBX 800 and gave the stock a "buy" rating in a research report on Friday, January 9th. Finally, Jefferies Financial Group started coverage on shares of Oxford Biomedica in a research report on Monday, March 23rd. They issued a "buy" rating and a GBX 827 target price for the company.

Oxford Biomedica Trading Up 0.5%

Oxford Biomedica stock opened at GBX 589 on Thursday. The company has a 50 day moving average price of GBX 620.81 and a 200 day moving average price of GBX 664.12. Oxford Biomedica has a 52 week low of GBX 270 and a 52 week high of GBX 952. The company has a debt-to-equity ratio of 116.74, a quick ratio of 1.67 and a current ratio of 2.20. The firm has a market capitalization of £712.10 million, a price-to-earnings ratio of -21.88 and a beta of 1.10.

Oxford Biomedica (LON:OXB - Get Free Report) last released its earnings results on Thursday, March 26th. The biopharmaceutical company reported GBX (26.92) earnings per share (EPS) for the quarter. Oxford Biomedica had a negative return on equity of 48.56% and a negative net margin of 17.85%. Research analysts forecast that Oxford Biomedica will post -31.0799998 EPS for the current year.

About Oxford Biomedica

Oxford Biomedica LSE: OXB is a quality and innovation-led cell and gene therapy CDMO with a mission to enable its clients to deliver life changing therapies to patients around the world. One of the original pioneers in cell and gene therapy, the Company has more than 25 years of experience in viral vectors; the driving force behind the majority of gene therapies. The Company collaborates with some of the world's most innovative pharmaceutical and biotechnology companies, providing viral vector development and manufacturing expertise in lentivirus, adeno-associated virus (AAV) and adenoviral vectors.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.